Interobserver agreement and assay reproducibility of folate receptor α expression in lung adenocarcinoma: A prognostic marker and potential therapeutic target

Archives of Pathology and Laboratory Medicine

Volumn 137, Issue 12, 2013, Pages 1747-1752

  Bremer, Ryan E ^a   Scoggin, Tatiana S ^a   Somers, Elizabeth B ^b   O'Shannessy, Daniel J ^b   Tacha, David E ^a  

^a Biocare Medical   (United States)

^b Morphotek Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84892736321     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: 10.5858/arpa.2013-0039-OA     Document Type: Article

References (19)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90.
2. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61(4):212-236.
3. Siegel R, De Santis C, Virgo K, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012;62(4):220-241.
4. Cagle PT, Chirieac LR. Advances in treatment of lung cancer with targeted therapy. Arch Pathol Lab Med. 2012;136(5):504-509.
5. Low PS, Kularatne SA. Folate-targeted therapeutic and imaging agents for cancer. Curr Opin Chem Biol. 2009;13(3):256-262.
6. Konner JA, Bell-McGuinn KM, Sabbatini P, et al. Farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a phase I study. Clin Cancer Res. 2010;16(21):5288-5295.
7. Elnakat H, Ratnam M. Distribution, functionality and gene regulation of folate receptor isoforms: implications in targeted therapy. Adv Drug Deliv Rev. 2004;56(8):1067-1084.
8. O'Shannessy DJ, Yu G, Smale R, et al. Folate receptor alpha expression in lung cancer: diagnostic and prognostic significance. Oncotarget. 2012;3(4):414-425.
9. Cagle PT, Zhai QJ, Murphy L, Low PS. Folate receptor in adenocarcinoma and squamous cell carcinoma of the lung: potential target for folate-linked therapeutic agents [published online ahead of print September 14, 2012]. Arch Pathol Lab Med. 2013;137(2):241-244.
10. Nunez MI, Behrens C, Woods D et al. High expression of folate receptor alpha in lung cancer correlates with adenocarcinoma histology and EGFR mutation. J Thorac Oncol. 2012;7(5):833-840.
11. Toffoli G, Cernigoi C, Russo A, Gallo A, Bagnoli M, Boiocchi M. Overexpression of folate binding protein in ovarian cancers. Int J Cancer. 1997;74(2):193-198.
12. O'Shannessy DJ, Somers EB, Maltzman J, Smale R, Fu YS. Folate receptor alpha (FRA) expression in breast cancer: identification of a new molecular subtype and association with triple negative disease. Springer Plus. 2012;1:22.
13. O'Shannessy DJ, Somers EB, Smale R, Fu YS. Expression of folate receptora (FRA) in gynecologic malignancies and its relationship to the tumor type. Int J Gynecol Pathol. In press.
14. Iwakiri S, Sonobe M, Nagai S, Hirata T, Wada H, Miyahara R. Expression status of folate receptor alpha is significantly correlated with prognosis in nonsmall-cell lung cancers. Ann Surg Oncol. 2008;15(3):889-899.
15. Toffoli G, Russo A, Gallo A, et al. Expression of folate binding protein as a prognostic factor for response to platinum-containing chemotherapy and survival in human ovarian cancer. Int J Cancer. 1998;79(2):121-126.
16. Hartmann LC, Keeney GL, Lingle WL, et al. Folate receptor overexpression is associated with poor outcome in breast cancer. Int J Cancer. 2007;121(5):938-942.
17. O'Shannessy, DJ, Somers ES, Albone E, et al. Characterization of the human folate receptor alpha via novel antibody-based probes. Oncotarget. 2011;2(12):1227-1243.
18. Christoph DC, Reyna-Asuncion B, Hassan B, et al. Significance of folate receptor alpha and thymidylate synthase protein expression in patients with nonsmall-cell lung cancer treated with pemetrexed. J Thorac Oncol. 2013;8(1):19-30.
19. Clopper CJ, Pearson ES. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika. 1934;26:404-413.